Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Asociación para Evitar la Ceguera en México

Status and phase: Withdrawn; Phase 3; Phase 2

Conditions: Central Serous Chorioretinopathy

Treatments: Drug: Intravitreal injection of Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00418431

APEC-0016

Details and patient eligibility

About

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment.

The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

Sex: All

Ages: 20 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Any visual acuity.
• Central serous chorioretinopathy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)